Using the provided mixing cup, combine 10 mL of water and the entire contents of one packet of ISENTRESS for oral suspension and mix. Exposures for pediatric subjects weighing at least 40 kg administered ISENTRESS HD are predicted to be comparable to adult exposures observed from Phase III ONCEMRK.
Of the 126 subjects, 96 received the recommended dose of ISENTRESS [see DOSAGE AND ADMINISTRATION].
Raltegravir can be taken either twice daily or once daily, depending on the form, with or without food.
Even with the newer RAL HD version that was approved in 2017, while it can be dosed once daily, it requires taking two pills plus being combined with other medications. have a history of a muscle disorder called rhabdomyolysis or myopathy, have increased levels of creatine kinase in your blood.
There are two different forms of raltegravir in the U.S.: Isentress – 400 mg tablets, red ovals with “227” printed on one side. Do not open the packets until ready for use. Revised: March 2018. In addition, the film coating contains the following inactive ingredients: black iron oxide, polyethylene glycol 3350, polyvinyl alcohol, red iron oxide, talc and titanium dioxide. Reported in treatment-naive Subjects. 258-4263.
Coadministration of ISENTRESS with drugs that inhibit UGT1A1 may increase plasma levels of raltegravir and coadministration of ISENTRESS with drugs that induce UGT1A1, such as rifampin, may reduce plasma levels of raltegravir (see Table 11). *Fasting (non-random) laboratory tests at Week 240. ISENTRESS film-coated tablets, chewable tablets and for oral suspension should be taken by mouth and may be taken with or without food [see CLINICAL PHARMACOLOGY].
In ONCEMRK, subjects received ISENTRESS HD 1200 mg once daily (n=531) or ISENTRESS 400 mg twice daily (n=266) both in combination with emtricitabine (+) tenofovir disoproxil fumarate. Your child’s dose will change over time. Coadministration is not recommended. Stay under the care of your doctor during treatment with ISENTRESS or ISENTRESS HD.
For more details on preparation and administration of the suspension, see, virologically suppressed on In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sixteen neonates were enrolled in Cohort 1 (10 were exposed and 6 were unexposed to raltegravir in utero) and 26 in Cohort 2 (all unexposed to raltegravir in utero); all infants received a standard of care antiretroviral drug regimen for prevention of mother to child transmission. The tablet may also contain trace amount of carnauba wax. Where can I find more information about raltegravir? Each 100 mg chewable tablet of ISENTRESS for oral administration contains 108.6 mg of raltegravir (as potassium salt), equivalent to 100 mg of raltegravir free phenol and the following inactive ingredients: ammonium hydroxide, crospovidone, ethylcellulose 20 cP, fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate, mannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and artificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG 400, red iron oxide, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol, sucralose and yellow iron oxide.
talc and titanium dioxide. are breastfeeding or plan to breastfeed.
People do not like ingesting pills, period. In drug interaction studies, there was no effect of raltegravir on the PK of ethinyl estradiol, methadone, midazolam or boceprevir. The extent to which ISENTRESS may be dialyzable is unknown. Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including ISENTRESS. Clinical studies of ISENTRESS/ISENTRESS HD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Maximum daily dose is 100 mg taken by mouth twice daily. years and ≥25 kg (87), Notes: ISENTRESS BID, ISENTRESS HD and Efavirenz were administered with emtricitabine (+) tenofovir disoproxil fumarate. Of the 26 treated subjects, 23 subjects were included in the Week 24 and 48 efficacy analyses, respectively.
Similarly, raltegravir is not an inhibitor (IC50>50 μM) of UGT1A1 or UGT2B7, and raltegravir does not inhibit P-glycoprotein-mediated transport.
In feces, only raltegravir was present, most of which is likely derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species. are pregnant or plan to become pregnant. Raltegravir is approximately 83% bound to human plasma protein over the concentration range of 2 to 10 μM. Call your doctor right away if you have any of the following signs or symptoms of liver problems: The most common side effects of ISENTRESS and ISENTRESS HD include: Less common side effects of ISENTRESS and ISENTRESS HD include: Tell your doctor right away if you get unexplained muscle pain, tenderness, or weakness during treatment with ISENTRESS or ISENTRESS HD. They are supplied as follows: NDC 0006-0473-61 unit-of-use bottles of 60. There were 797 subjects included in the efficacy and safety analyses.
Isentress HD was approved by the FDA in 2017, a full decade after the original was put on the market. Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes, organ dysfunction, including hepatic failure. If you take too much raltegravir, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room. (eye sen tris HD) A model of the molecular structure of raltegravir (a.k.a. Systemic exposure (AUC) at 600 mg/kg/day was approximately 3 times higher than exposure at the MRHD of 1200 mg. You can ask your doctor or pharmacist for a list of medicines that interact with ISENTRESS and ISENTRESS HD. Single-dose and steady-state pharmacokinetics of 1200 mg for 2 formulations of raltegravir were characterized in 2 open-label phase 1 studies in healthy male and female subjects aged 18 to 55 years. dosing twice daily (see Table 3), If at least 4 weeks of age What are ISENTRESS and ISENTRESS HD and how is it used?
More information about raltegravir is available: Merck & Co., Inc.
*Hepatitis B virus surface antigen positive or hepatitis C virus antibody positive. home NDC 0006-3603-01 individual packet. Instruct parents and/or caregivers that ISENTRESS for oral suspension should be administered within 30 minutes of mixing. Make sure you follow your doctor’s instructions.
In ONCEMRK, clinical adverse reactions of all intensities (mild, moderate and severe) occurring in ≥2% of subjects on ISENTRESS HD or ISENTRESS 400 mg twice daily through Week 96 also include abdominal pain, diarrhea, vomiting, and decreased appetite. The 100 mg chewable tablet also contains red iron oxide. In STARTMRK, subjects received ISENTRESS 400 mg twice daily (N=281) or efavirenz (EFV) 600 mg at bedtime (N=282) both in combination with emtricitabine (+) tenofovir disoproxil fumarate, (N=282). NDC 0006-3603-60 unit of use carton with 60 packets. However, the twice-a-day dosing became problematic over the years, as more single tablet regimens (STR) and once-daily dosing regimens became available, eventually becoming a preferred option for many people.
NDC 0006-3603-01 individual packet. This median proportion was approximately 3-fold lower than the free fraction of raltegravir in plasma. No hepatic impairment study has been conducted with ISENTRESS HD and therefore administration in subjects with hepatic impairment is not recommended. The above Patient Version drug summary is based on the following FDA label(s): Tablet (chewable), tablet (film coated), granule for oral suspension.
Similarly, darunavir use in OBT in darunavir-naïve subjects was counted as one active drug in OBT.
In a combined embryo/fetal and pre/postnatal development study, raltegravir was administered orally to rats at doses of 100, 300, 600 mg/kg/day on gestation day 6 to 20 or from gestation day 6 to lactation day 20. Table 19: Virologic Outcomes of Randomized Treatment in STARTMRK and ONCEMRK (Snapshot Algorithm) in HIV treatment-naive Adults. Isentress HD is FDA-approved in the United States to be taken as two 600-mg tablets, once daily, also with or without food. In the ONCEMRK trial, ISENTRESS HD 1200 mg (2 x 600 mg) once daily demonstrated consistent virologic and immunologic efficacy relative to ISENTRESS 400 mg twice daily, both in combination with emtricitabine (+) tenofovir disoproxil fumarate, across demographic and baseline prognostic factors, including: baseline HIV RNA levels >100,000 copies/mL and demographic groups (including age, gender, race, ethnicity and region), concomitant proton pump inhibitors/H2 blockers use and viral subtypes (comparing non-clade B as a group to clade B).